MX2009004763A - Moduladores aloestericos del receptor de adenosina a1. - Google Patents
Moduladores aloestericos del receptor de adenosina a1.Info
- Publication number
- MX2009004763A MX2009004763A MX2009004763A MX2009004763A MX2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine receptor
- formula
- allosteric modulators
- compounds
- pain
- Prior art date
Links
- 101150007969 ADORA1 gene Proteins 0.000 title abstract 3
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000020446 Cardiac disease Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85850506P | 2006-11-13 | 2006-11-13 | |
| US11/938,465 US7855209B2 (en) | 2006-11-13 | 2007-11-12 | Allosteric modulators of the A1 adenosine receptor |
| US11/938,514 US7897596B2 (en) | 2006-11-13 | 2007-11-12 | Allosteric modulators of the A1 adenosine receptor |
| PCT/US2007/084490 WO2008063984A2 (en) | 2006-11-13 | 2007-11-13 | Allosteric modulators of the a1 adenosine receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004763A true MX2009004763A (es) | 2009-05-21 |
Family
ID=39430473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004763A MX2009004763A (es) | 2006-11-13 | 2007-11-13 | Moduladores aloestericos del receptor de adenosina a1. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2081575A4 (enExample) |
| JP (1) | JP2010509402A (enExample) |
| KR (1) | KR20090112627A (enExample) |
| AU (1) | AU2007323888A1 (enExample) |
| BR (1) | BRPI0718520A2 (enExample) |
| CA (1) | CA2669447A1 (enExample) |
| IL (1) | IL198402A0 (enExample) |
| MX (1) | MX2009004763A (enExample) |
| WO (1) | WO2008063984A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739588B (zh) * | 2014-01-04 | 2015-07-01 | 新发药业有限公司 | 一种2-氨基噻吩衍生物的简便合成方法 |
| US10434099B2 (en) | 2016-09-22 | 2019-10-08 | The National Institute for Biotechnology in the Negev Ltd. | Methods for treating central nervous system disorders using VDAC inhibitors |
| WO2017046794A1 (en) | 2015-09-14 | 2017-03-23 | The National Institute for Biotechnology in the Negev Ltd. | Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction |
| US10787423B2 (en) | 2015-09-14 | 2020-09-29 | The National Institute For Biotechnolgy In The Negev Ltd. | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
| JP7365237B2 (ja) | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | シグマ－２受容体の新規調節物質およびその使用方法 |
| EP3600289A4 (en) | 2017-03-21 | 2020-08-05 | Temple University - Of The Commonwealth System of Higher Education | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5332732A (en) * | 1992-09-11 | 1994-07-26 | Mcneilab, Inc. | Thiophene and pyridine antipsychotic agents |
| ES2092737T3 (es) * | 1992-10-29 | 1996-12-01 | Hoechst Ag | Procedimiento para la preparacion de compuestos bromometil-aromaticos. |
| US5939432A (en) * | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
-
2007
- 2007-11-13 JP JP2009537305A patent/JP2010509402A/ja not_active Withdrawn
- 2007-11-13 AU AU2007323888A patent/AU2007323888A1/en not_active Abandoned
- 2007-11-13 WO PCT/US2007/084490 patent/WO2008063984A2/en not_active Ceased
- 2007-11-13 BR BRPI0718520-0A patent/BRPI0718520A2/pt not_active IP Right Cessation
- 2007-11-13 MX MX2009004763A patent/MX2009004763A/es not_active Application Discontinuation
- 2007-11-13 CA CA002669447A patent/CA2669447A1/en not_active Abandoned
- 2007-11-13 KR KR1020097009765A patent/KR20090112627A/ko not_active Withdrawn
- 2007-11-13 EP EP07864306A patent/EP2081575A4/en not_active Withdrawn
-
2009
- 2009-04-26 IL IL198402A patent/IL198402A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL198402A0 (en) | 2010-02-17 |
| JP2010509402A (ja) | 2010-03-25 |
| AU2007323888A1 (en) | 2008-05-29 |
| WO2008063984A3 (en) | 2008-08-14 |
| BRPI0718520A2 (pt) | 2013-11-19 |
| EP2081575A4 (en) | 2010-01-06 |
| CA2669447A1 (en) | 2008-05-29 |
| WO2008063984A2 (en) | 2008-05-29 |
| KR20090112627A (ko) | 2009-10-28 |
| EP2081575A2 (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
| UA103198C2 (en) | Squaramide derivatives as cxcr2 antagonists | |
| JO2686B1 (en) | Vehicles | |
| NZ592544A (en) | Isonicotinamide orexin receptor antagonists | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
| IL232619A0 (en) | Preparations suitable for the treatment of diseases of the spine and related disorders and conditions | |
| EP2554540A3 (en) | 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | |
| WO2010045258A3 (en) | Spirocyclic gpr40 modulators | |
| MX2010005703A (es) | Antagonistas de acido nucleico entrelazado que eligen como objetivo al receptor de androgeno. | |
| MX2009005363A (es) | Pirimidinas y su uso como antagonistas del receptor cxcr2. | |
| JO2701B1 (en) | Vehicles | |
| WO2008070111A3 (en) | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof | |
| WO2008063984A3 (en) | Allosteric modulators of the a1 adenosine receptor | |
| PL2303330T3 (pl) | Kompozycje farmaceutyczne do leczenia choroby Parkinsona | |
| WO2008059370A8 (en) | Substituted bicyclocarboxyamide compounds | |
| IL209896A0 (en) | Compounds for treating symptoms associated with parkinson's disease | |
| EA201001404A1 (ru) | Амиды 5-оксо-2,3,4,5-тетрагидробензо[b]оксепин-4-карбоновой кислоты и амиды 2,3-дигидробензо[b]оксепин-4-карбоновой кислоты для лечения и предотвращения диабета 1 и 2 типа | |
| WO2007108936A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| SI2024368T1 (sl) | Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine | |
| PY0604615A (es) | Forma cistalina gamma-d de clorhidrato de ivabradina, su procedimiento de preparación sus composiciones farmaceuticas y su utilización en la fabricación de medicamentos bradicardi | |
| MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| WO2008045371A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| WO2008050199A3 (en) | Substituted phenylmethyl bicyclocarboxyamide compounds | |
| WO2008091934A3 (en) | Fructose 1, 6 bisphosphate - a novel anticonvulsant drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |